Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>An important feature of severe acute respiratory syndrome coronavirus 2 pathogenesis is COVID-19-associated coagulopathy, characterised by increased thrombotic and microvascular complications. Previous studies have suggested a role for endothelial cell injury in COVID-19-associated coagulopathy. To determine whether endotheliopathy is involved in COVID-19-associated coagulopathy pathogenesis, we assessed markers of endothelial cell and platelet activation in critically and non-critically ill patients admitted to the hospital with COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In this single-centre cross-sectional study, hospitalised adult (≥18 years) patients with laboratory-confirmed COVID-19 were identified in the medical intensive care unit (ICU) or a specialised non-ICU COVID-19 floor in our hospital. Asymptomatic, non-hospitalised controls were recruited as a comparator group for biomarkers that did not have a reference range. We assessed markers of endothelial cell and platelet activation, including von Willebrand Factor (VWF) antigen, soluble thrombomodulin, soluble P-selectin, and soluble CD40 ligand, as well as coagulation factors, endogenous anticoagulants, and fibrinolytic enzymes. We compared the level of each marker in ICU patients, non-ICU patients, and controls, where applicable. We assessed correlations between these laboratory results with clinical outcomes, including hospital discharge and mortality. Kaplan–Meier analysis was used to further explore the association between biochemical markers and survival.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>68 patients with COVID-19 were included in the study from April 13 to April 24, 2020, including 48 ICU and 20 non-ICU patients, as well as 13 non-hospitalised, asymptomatic controls. Markers of endothelial cell and platelet activation were significantly elevated in ICU patients compared with non-ICU patients, including VWF antigen (mean 565% [SD 199] in ICU patients <em>vs</em> 278% [133] in non-ICU patients; p<0·0001) and soluble P-selectin (15·9 ng/mL [4·8] <em>vs</em> 11·2 ng/mL [3·1]; p=0·0014). VWF antigen concentrations were also elevated above the normal range in 16 (80%) of 20 non-ICU patients. We found mortality to be significantly correlated with VWF antigen (<em>r</em> = 0·38; p=0·0022) and soluble thrombomodulin (<em>r</em> = 0·38; p=0·0078) among all patients. In all patients, soluble thrombomodulin concentrations greater than 3·26 ng/mL were associated with lower rates of hospital discharge (22 [88%] of 25 patients with low concentrations <em>vs</em> 13 [52%] of 25 patients with high concentrations; p=0·0050) and lower likelihood of survival on Kaplan–Meier analysis (hazard ratio 5·9, 95% CI 1·9–18·4; p=0·0087).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>Our findings show that endotheliopathy is present in COVID-19 and is likely to be associated with critical illness and death. Early identification of endotheliopathy and strategies to mitigate its progression might improve outcomes in COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>This work was supported by a gift donation from Jack Levin to the Benign Hematology programme at Yale, and the National Institutes of Health.</p>

Multiplatform analyses reveal distinct drivers of systemic pathogenesis in adult versus pediatric severe acute COVID-19

The mechanism of multiple organ dysfunction syndrome in patients with COVID-19

The Mechanism of Multiple Organ Dysfunction Syndrome in Patients with COVID‐19

Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives

Pathophysiological pathway differences in children who present with COVID-19 ARDS compared to COVID -19 induced MIS-C

Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes

Emergency myelopoiesis distinguishes multisystem inflammatory syndrome in children from pediatric severe COVID-19

Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children

Multi-omic profiling of plasma reveals molecular alterations in children with COVID-19

Cell-free DNA reveals distinct pathology of multisystem inflammatory syndrome in children (MIS-C)

Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study

Clinical characteristics, multiorgan dysfunction and outcomes of patients with COVID-19: a prospective case series

Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

COVID-19 Severity is Associated with Immunopathology and Multi-Organ Damage

Single-cell transcriptomic analysis reveals a systemic immune dysregulation in COVID-19-associated pediatric encephalopathy

Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

Role of matrix metalloproteinases in multi-system inflammatory syndrome and acute COVID-19 in children

Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2